Abstract: This disclosure provides genomics-based methods that can be used to identify, quantify, and characterize rare cell types, including circulating tumor cells.

Abstract: This disclosure provides genomics-based methods that can be used to identify, quantify, and characterize rare cell types, including circulating tumor cells.

Abstract: The present invention provides methods, compositions and kits for the generation of next generation sequencing (NGS) libraries in which non-desired nucleic acid sequences have been depleted or substantially reduced. The methods, compositions and kits provided herein are useful, for example, for the production of libraries from total RNA with reduced ribosomal RNA and for the reduction of common mRNA species in expression profiling from mixed samples where the mRNAs of interest are present at low levels. The methods of the invention can be employed for the elimination of non-desired nucleic acid sequences in a sequence-specific manner, and consequently, for the enrichment of nucleic acid sequences of interest in a nucleic acid library.

Abstract: The present invention provides methods, compositions and kits for the generation of next generation sequencing (NGS) libraries in which non-desired polynucleotides have been depleted or substantially reduced. The methods, compositions and kits provided herein are useful, for example, for the production of libraries from total RNA with reduced ribosomal RNA and for the reduction of common mRNA species in expression profiling from mixed samples where the mRNAs of interest are present at low levels. The methods of the invention can be employed for the elimination of non-desired polynucleotides in a sequence-specific manner, and consequently, for the enrichment of nucleic acid sequences of interest in a nucleic acid library.

Abstract: The invention provides methods and compositions, including kits, for directional nucleic acid amplification and sequencing. The invention further provides methods and compositions for the construction of directional cDNA libraries.

Abstract: The invention provides methods and compositions, including kits, for directional nucleic acid amplification and sequencing. The invention further provides methods and compositions for the construction of directional cDNA libraries.

Abstract: The present invention provides methods, compositions and kits for the generation of next generation sequencing (NGS) libraries in which non-desired nucleic acid sequences have been depleted or substantially reduced. The methods, compositions and kits provided herein are useful, for example, for the production of libraries from total RNA with reduced ribosomal RNA and for the reduction of common mRNA species in expression profiling from mixed samples where the mRNAs of interest are present at low levels. The methods of the invention can be employed for the elimination of non-desired nucleic acid sequences in a sequence-specific manner, and consequently, for the enrichment of nucleic acid sequences of interest in a nucleic acid library.

Abstract: The present invention provides methods for selectively amplifying a target population of nucleic acid molecules in a population of RNA template molecules (e.g., all mRNA molecules expressed in a cell type except for the most highly expressed mRNA species). The invention also provides a method of generating a population of oligonucleotide primers for transcriptome profiling of total RNA from a subject of interest.

Abstract: The present invention provides methods for selectively amplifying a target population of nucleic acid molecules (e.g., all mRNA molecules expressed in a cell type except for the most highly expressed mRNA species). The present invention also provides populations of oligonucleotides including the nucleic acid sequences set forth in SEQ ID NOS:1-933. These oligonucleotides can be used, for example, to prime the synthesis of cDNA molecules complementary to mRNA molecules isolated from mammalian blood without priming the synthesis of cDNA molecules complementary to globin mRNA, or ribosomal RNA molecules.

Abstract: The present invention provides methods for selectively amplifying a target population of nucleic acid molecules in a population of RNA template molecules (e.g., all mRNA molecules expressed in a cell type except for the most highly expressed mRNA species). The present invention also provides a first population of oligonucleotides including the nucleic acid sequences set forth in SEQ ID NOS:1-749 and a second population of oligonucleotides including the nucleic acid sequences set forth in SEQ ID NOS:750-1498. The first population of oligonucleotides can be used, for example, to prime the synthesis of first strand cDNA molecules complementary to mRNA molecules isolated from mammalian cells without priming the synthesis of cDNA molecules complementary to ribosomal RNA molecules.

Abstract: The present invention provides methods for selectively amplifying a target population of nucleic acid molecules in a population of RNA template molecules (e.g., all mRNA molecules expressed in a cell type except for the most highly expressed mRNA species). The invention also provides a method of generating a population of oligonucleotide primers for transcriptome profiling of total RNA from a subject of interest.

Abstract: The present invention provides methods for selectively amplifying a target population of nucleic acid molecules (e.g., all mRNA molecules expressed in a cell type except for the most highly expressed mRNA species). The present invention also provides populations of oligonucleotides including the nucleic acid sequences set forth in SEQ ID NOS:1-933. These oligonucleotides can be used, for example, to prime the synthesis of cDNA molecules complementary to mRNA molecules isolated from mammalian blood without priming the synthesis of cDNA molecules complementary to globin mRNA, or ribosomal RNA molecules.

Abstract: The present invention features nucleic acids and polypeptides encoding novel splice variant isoforms of calcium channel, voltage dependent, alpha-1G subunit (CACNA1G). The polynucleotide sequence of CACNA1Gsv1 is provided by SEQ ID NO 4. The amino acid sequence of CACNA1Gsv1 is provided by SEQ ID NO 5. The polynucleotide sequence of CACNA1Gsv2 is provided by SEQ ID NO 6. The amino acid sequence of CACNA1Gsv2 is provided by SEQ ID NO 7. The present invention also provides methods for using CACNA1Gsv1, CACNA1Gsv2 polynucleotides and proteins to screen for compounds that bind to CACNA1Gsv1, CACNA1Gsv2, respectively.

Abstract: The present invention features a nucleic acid and a polypeptide encoding a novel splice variant isoform of mitotic centromere-associated kinesin (MCAK). The polynucleotide sequence of MCAKsv1 is provided by SEQ ID NO 2. The amino acid sequence for MCAKsv1 is provided by SEQ ID NO 3. The present invention also provides methods for using MCAKsv1 polynucleotide and protein to screen for compounds that bind to MCAKsv1 and to screen for compounds that bind to other kinesin isoform polypeptides but not to MCAKsv1.

Abstract: The present invention features nucleic acids and polypeptides encoding four novel splice variant isoforms of PHKA2. The polynucleotide sequences of PHKA2sv3, PHKA2sv4, PHKA2sv6 and PHKA2sv7 are provided by SEQ ID NO 1, SEQ ID NO 3, SEQ ID NO 5 and SEQ ID NO 6, respectively. The amino acid sequences for PHKA2sv3, PHKA2sv4, and PHKA2sv7 are provided by SEQ ID NO 2, SEQ ID NO 4, and SEQ ID NO 7, respectively. The present invention also provides methods for using PHKA2sv3, PHKA2sv4, and PHKA2sv7 polynucleotides and proteins to screen for compounds that bind to PHKA2sv3, PHKA2sv4, and PHKA2sv7, respectively.

Abstract: The present invention features nucleic acids and polypeptides encoding a novel splice variant isoform of calcium channel, voltage dependent, alpha-1I subunit (CACNA1I). The polynucleotide sequence of CACNA1Isv1 is provided by SEQ ID NO 3. The amino acid sequence of CACNA1Isv1 is provided by SEQ ID NO 4. The present invention also provides methods for using CACNA1Isv1 polynucleotides and proteins to screen for compounds that bind to CACNA1Isv1.

Abstract: The present invention features nucleic acids and polypeptides encoding novel splice variant isoforms of acetyl-CoA carboxylase 2 (ACC2). The polynucleotide sequence of ACC2sv1 is provided by SEQ ID NO 3. The amino acid sequence of ACC2sv1 is provided by SEQ ID NO 4. The present invention also provides methods for using ACC2sv1 polynucleotides and proteins to screen for compounds that bind to ACC2sv1.

Abstract: The present invention features nucleic acids and polypeptides encoding a novel splice variant isoform of interleukin 4, subunit alpha (IL-4R?). The polynucleotide sequence of IL-4R?sv1 is provided by SEQ ID NO 4. The amino acid sequence for IL-4R?sv1 is provided by SEQ ID NO 5. The present invention also provides methods for using IL-4R?sv1 polynucleotides and proteins to screen for compounds that bind to IL-4R?sv1.

Abstract: The present invention features nucleic acids and polypeptides encoding a novel splice variant isoform of cell division cycle 25A (Cdc25A) phosphatase. The polynucleotide sequence of Cdc25Asv1 is provided by SEQ ID NO:2. The amino acid sequence for Cdc25Asv1 is provided by SEQ ID NO:3. The present invention also provides methods for using Cdc25Asv1 polynucleotides and proteins to screen for compounds that bind to Cdc25Asv1.

Abstract: The present invention features nucleic acids and polypeptides encoding three novel splice variant isoforms of sodium channel, voltage gated, type VIII, alpha (SCN8A). The polynucleotide sequences of SCN8Asv1.1, SCN8Asv1.2 and SCN8Asv2 are provided by SEQ ID NO 3, SEQ ID NO 5, and SEQ ID NO 7, respectively. The amino acid sequences for SCN8Asv1.1, SCN8Asv1.2, and SCN8Asv2 are provided by SEQ ID NO 4, SEQ ID NO 6, and SEQ ID NO 8, respectively. The present invention also provides methods for using SCN8Asv1.1, SCN8Asv1.2, and SCN8Asv2 polynucleotides and proteins to screen for compounds that bind to SCN8Asv1.1, SCN8Asv1.2, and SCN8Asv2, respectively.